{"DataElement":{"publicId":"3776094","version":"1","preferredName":"Chemosensitivity Assay Agent Name","preferredDefinition":"The agent (active power or cause) name used in a laboratory test to see how well a particular chemotherapy drug kills cancer cells which may result in choosing the best drug or drugs for the treatment of the specific cancer being treated.","longName":"CHEMO_ASSAY_AGENT_NAME","context":"OHSU Knight","contextVersion":"1","DataElementConcept":{"publicId":"3776093","version":"1","preferredName":"Chemosensitivity Assay Agent","preferredDefinition":"A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"3776091v1.0:2514627v1.0","context":"OHSU Knight","contextVersion":"1","ObjectClass":{"publicId":"3776091","version":"1","preferredName":"Chemosensitivity Assay","preferredDefinition":"A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated.","longName":"C18215","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemosensitivity Assay","conceptCode":"C18215","definition":"A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84A65B-7AFE-2E67-E040-BB89AD432F22","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2514627","version":"1","preferredName":"Agent","preferredDefinition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI)","longName":"C1708","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1BB1AAFE-FB3A-4FE3-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-08-23","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-08-23","modifiedBy":"ONEDATA","dateModified":"2006-08-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84A65B-7B0C-2E67-E040-BB89AD432F22","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3776073","version":"1","preferredName":"Chemosensitivity Assay Agent Name","preferredDefinition":"A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated._An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect._The words or language units by which a thing is known.","longName":"3776073v1.0","context":"OHSU Knight","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Dasatinib","valueDescription":"Dasatinib","ValueMeaning":{"publicId":"2737464","version":"1","preferredName":"Dasatinib","longName":"2737464","preferredDefinition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Dasatinib","conceptCode":"C38713","definition":"An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases.  Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with a variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C312-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE84372B-DC06-3F77-E040-BB89AD432E57","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","deletedIndicator":"No"},{"value":"Nilotinib","valueDescription":"Nilotinib","ValueMeaning":{"publicId":"2737467","version":"1","preferredName":"Nilotinib","longName":"2737467","preferredDefinition":"An orally available aminopyrimidine with antineoplastic activity. Designed to overcome imatinib resistance, Nilotinib is a tyrosine kinase inhibitor that binds to and inhibits the Bcr-Abl fusion protein, an abnormal chimeric tyrosine kinase expressed in Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases for platelet-derived growth factor (PDGF) and for c-kit, a receptor tyrosine kinase activated in gastrointestinal stromal tumor (GIST). Nilotinib interrupts phosphorylation of these tyrosine kinases and their downstream signaling targets, resulting in decreased cellular proliferation and the induction of apoptosis. This agent is more potent than imatinib against Ph+ CML cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nilotinib","conceptCode":"C48375","definition":"An orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. This agent also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). With a binding mode that is energetically more favorable than that of imatinib, nilotinib has been shown to have an approximately 20-fold increased potency in kinase and proliferation assays compared to imatinib.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"497238FA-C391-26E6-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"NYCHM","dateCreated":"2008-03-27","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE84372B-DC11-3F77-E040-BB89AD432E57","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","deletedIndicator":"No"},{"value":"Sunitinib","valueDescription":"Sunitinib","ValueMeaning":{"publicId":"3776074","version":"1","preferredName":"Sunitinib","longName":"3776074","preferredDefinition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sunitinib","conceptCode":"C71622","definition":"An indolinone derivative and tyrosine kinase inhibitor with potential antineoplastic activity. Sunitinib blocks the tyrosine kinase activities of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor b (PDGFRb), and c-kit, thereby inhibiting angiogenesis and cell proliferation.  This agent also inhibits the phosphorylation of Fms-related tyrosine kinase 3 (FLT3), another receptor tyrosine kinase expressed by some leukemic cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC1C-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE84372B-DC35-3F77-E040-BB89AD432E57","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","deletedIndicator":"No"},{"value":"Sorafenib","valueDescription":"Sorafenib","ValueMeaning":{"publicId":"3380164","version":"1","preferredName":"Sorafenib","longName":"3380164","preferredDefinition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sorafenib","conceptCode":"C61948","definition":"A synthetic compound targeting growth signaling and angiogenesis. Sorafenib blocks the enzyme RAF kinase, a critical component of the RAF/MEK/ERK signaling pathway that controls cell division and proliferation; in addition, sorafenib inhibits the VEGFR-2/PDGFR-beta signaling cascade, thereby blocking tumor angiogenesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B97A2A6B-9613-1351-E040-BB89AD432684","latestVersionIndicator":"Yes","beginDate":"2012-02-21","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-02-21","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE84372B-DC49-3F77-E040-BB89AD432E57","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","deletedIndicator":"No"},{"value":"Ponatinib","valueDescription":"Ponatinib","ValueMeaning":{"publicId":"3776076","version":"1","preferredName":"Ponatinib","longName":"3776076","preferredDefinition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Ponatinib","conceptCode":"C95777","definition":"An orally bioavailable multitargeted receptor tyrosine kinase (RTK) inhibitor with potential antiangiogenic and antineoplastic activities. Ponatinib inhibits unmutated and all mutated forms of Bcr-Abl, including T315I, the highly drug therapy-resistant missense mutation of Bcr-Abl. This agent also inhibits other tyrosine kinases including those associated with vascular endothelial growth factor receptors (VEGFRs) and fibroblast growth factor receptors (FGFRs); in addition, it inhibits the tyrosine kinase receptor TIE2 and FMS-related tyrosine kinase receptor-3 (Flt3). RTK inhibition by ponatinib may result in the inhibition of cellular proliferation and angiogenesis and may induce cell death. Bcr-Abl is a fusion tyrosine kinase encoded by the Philadelphia chromosome.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DC57-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"DE84372B-DC70-3F77-E040-BB89AD432E57","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2435024","version":"1","preferredName":"Drug or Chemical","preferredDefinition":"A category of organic or inorganic substances, elements, and isotopes used in research or for the prevention, diagnosis, and/or treatment of disease states. Includes biologically active substances that are either synthetically manufactured or endogenous substances extracted and processed to be reintroduced into an organism. Chemicals and drugs also include hazardous substances, and naturally occurring or synthetically produced substances required to maintain life.","longName":"C1908","context":"NCIP","contextVersion":"1","origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"07431EBC-FB04-25D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-12-06","endDate":null,"createdBy":"CURTIST","dateCreated":"2005-12-06","modifiedBy":"SBR","dateModified":"2006-12-20","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3776072","version":"1","preferredName":"Chemosensitivity Assay Agent Name","preferredDefinition":"A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated.:An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect. (NCI):The words or language units by which a thing is known.","longName":"C18215:C1708:C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chemosensitivity Assay","conceptCode":"C18215","definition":"A laboratory test to see how well a particular chemotherapy drug kills cancer cells. The test is done after the tumor cells are removed from the body. The assay may help in choosing the best drug or drugs for the cancer being treated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Agent","conceptCode":"C1708","definition":"An active power or cause (as principle, substance, physical or biological factor, etc.) that produces a specific effect.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DBE0-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"ONEDATA","dateModified":"2013-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84372B-DBF1-3F77-E040-BB89AD432E57","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"HARTLEYG","dateModified":"2013-07-02","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[{"name":"CHEMO_ASSAY_AGENT_NAME","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"Result(s) of study participan","type":"Preferred Question Text","description":"Result(s) of study participant's chemosensitivity testing","url":null,"context":"OHSU Knight"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"DE84A65B-7B1E-2E67-E040-BB89AD432F22","latestVersionIndicator":"Yes","beginDate":"2013-06-06","endDate":null,"createdBy":"HARTLEYG","dateCreated":"2013-06-06","modifiedBy":"FORMBUILDER","dateModified":"2015-09-14","changeDescription":"OHSU 7195 ghd 06.06.13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}